US Markets
Home›US Markets›M&A & Deals›Conexeu Sciences targets FDA 510(k) filing for bioreso…
Conexeu Sciences targets FDA 510(k) filing for bioresorbable scaffold
The preclinical-stage regenerative tissue company plans an early-2027 510(k) submission as it advances a predicate-based U.S. regulatory path.
Conexeu Sciences Inc. (Nasdaq: CNXU) is developing tissue-regeneration technology aimed at wound care, aesthetics, oral health, veterinary medicine, and reconstruction, positioning the platform to address large-volume tissue restoration needs not fully served by current fillers and injectables, according to a fireside chat hosted by IPO Edge.
The company said widespread use of GLP-1 weight-loss drugs is helping drive demand for treatments that can restore lost facial and body volume. Conexeu plans to use a single core technology across multiple medical applications, built around a bioresorbable regenerative scaffold intended as a potential alternative to silicone breast implants, and it is targeting multi-billion-dollar markets including wound care, periodontal applications, and tissue restoration after GLP-1-associated volume changes.
Conexeu described its regulatory approach as predicate-based, with an anticipated U.S. FDA 510(k) submission in early 2027 for its initial indication, subject to review. It also flagged additional data publications, breast program progress, and expansion into dental and veterinary markets as upcoming catalysts.
Latest closeNasdaq Comp. 25,373.85 ▲1.0%